Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | APAF1 | O14727 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ECE1 | P42892 | 5/20 | 0.65 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.64 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170877 | 1.00 | KDM4E (0.69) | KDM4EMAPTAPAF1POLBRECQL | |
| Water SCHEMBL5384989 | 0.99 | KDM4E (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL991035 | 0.99 | KDM4E (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| Water SCHEMBL5384991 | 0.99 | KDM4E (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL991039 | 0.99 | KDM4E (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| Glutaral SCHEMBL5081526 | 0.90 | ALOX15 (0.61) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL30782236 | 0.90 | ALOX15 (0.70) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL2167226 | 0.88 | ALOX15 (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL1755294 | 0.88 | ALOX15 (0.68) | KDM4EMAPTAPAF1POLBRECQL | |
| SCHEMBL3873860 | 0.88 | KDM4E (0.61) | KDM4EMAPTAPAF1POLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| EP-4709360-A1 | MULTIPHASE TABLET HAVING SLEEP-PROMOTING EFFECT | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH (DE) | 2026-03-18 | — | — | EP | claimed |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-05 | — | — | US | claimed |
| CN-119842835-A | Application of mutation site as target spot in preparation of fluorine-containing hydroxyl tryptophan | 天津大学 | 2025-04-18 | — | — | CN | claimed |
| WO-2025045432-A1 | MULTIPHASE TABLET HAVING SLEEP-PROMOTING EFFECT | MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBH (DE) | 2025-03-06 | — | — | WO | claimed |
| CN-118979005-B | 5-Hydroxytryptophan production strain and construction method and application thereof | 天津科技大学 | 2025-02-18 | — | — | CN | claimed |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | claimed |
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | claimed |
| EP-3661938-B1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RES GMBH (DE) | 2025-01-15 | — | — | EP | claimed |
| WO-2024258190-A1 | HAIR DYE COMPOSITION FOR PREMATURE GRAY HAIR AND METHOD FOR PREPARING SAME | 코스맥스 주식회사 | 2024-12-19 | — | — | WO | claimed |
| US-6232336-B1 | HYPOTENSIVE AGENTS; NEUROTRANSMISSION; CYTOTOXICITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-05-15 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000068413-A1 | HALO- OR HYDROXY-SUBSTITUTED NOCATHIACIN ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-16 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1000023-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999061038-A1 | COMPOSITION HAVING THERAPEUTIC AND/OR NUTRITIONALLY ACTIVE SUBSTITUENT | ADAMS FOOD LTD. (US) | 1999-12-02 | — | — | WO | claimed |
| WO-1999001427-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 1999-01-14 | — | — | WO | claimed |
| US-5225529-A | Central nervous system disorders such as Alzheimer*s disease | FARMHISPANIA S.A. (ES) | 1993-07-06 | — | — | US | claimed |
| EP-0381070-A1 | Synthetic amphiphilic glycoconjugates for neurological use | FARMHISPANIA S.A. (ES) | 1990-08-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | KDM4E 1143/4885MAPT 1741/4885APAF1 2125/4885 |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | AANAT, HNMT, HTR6 | KDM4E 3298/4885MAPT 1033/4885APAF1 3674/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | KDM4E 1199/4885MAPT 79/4885APAF1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.